PCM
BSX.PRA

Palisade Capital Management’s Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A BSX.PRA Stock Holding History

Palisade Capital Management’s Portfolio BSX.PRA Stock Details BSX.PRA Fund Activity
Upgrade to unlock
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
2023
Q1 		$2.67M Sell
2022
Q4 		$4.18M Hold
2022
Q3 		$3.73M Buy
2022
Q2 		$2.79M Hold
2022
Q1 		$3.2M Buy